Cargando…

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach

MOTIVATION: Proteomics profiling is increasingly being used for molecular stratification of cancer patients and cell-line panels. However, systematic assessment of the predictive power of large-scale proteomic technologies across various drug classes and cancer types is currently lacking. To that en...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Mehreen, Khan, Suleiman A, Wennerberg, Krister, Aittokallio, Tero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905617/
https://www.ncbi.nlm.nih.gov/pubmed/29186355
http://dx.doi.org/10.1093/bioinformatics/btx766
_version_ 1783315291971780608
author Ali, Mehreen
Khan, Suleiman A
Wennerberg, Krister
Aittokallio, Tero
author_facet Ali, Mehreen
Khan, Suleiman A
Wennerberg, Krister
Aittokallio, Tero
author_sort Ali, Mehreen
collection PubMed
description MOTIVATION: Proteomics profiling is increasingly being used for molecular stratification of cancer patients and cell-line panels. However, systematic assessment of the predictive power of large-scale proteomic technologies across various drug classes and cancer types is currently lacking. To that end, we carried out the first pan-cancer, multi-omics comparative analysis of the relative performance of two proteomic technologies, targeted reverse phase protein array (RPPA) and global mass spectrometry (MS), in terms of their accuracy for predicting the sensitivity of cancer cells to both cytotoxic chemotherapeutics and molecularly targeted anticancer compounds. RESULTS: Our results in two cell-line panels demonstrate how MS profiling improves drug response predictions beyond that of the RPPA or the other omics profiles when used alone. However, frequent missing MS data values complicate its use in predictive modeling and required additional filtering, such as focusing on completely measured or known oncoproteins, to obtain maximal predictive performance. Rather strikingly, the two proteomics profiles provided complementary predictive signal both for the cytotoxic and targeted compounds. Further, information about the cellular-abundance of primary target proteins was found critical for predicting the response of targeted compounds, although the non-target features also contributed significantly to the predictive power. The clinical relevance of the selected protein markers was confirmed in cancer patient data. These results provide novel insights into the relative performance and optimal use of the widely applied proteomic technologies, MS and RPPA, which should prove useful in translational applications, such as defining the best combination of omics technologies and marker panels for understanding and predicting drug sensitivities in cancer patients. AVAILABILITY AND IMPLEMENTATION: Processed datasets, R as well as Matlab implementations of the methods are available at https://github.com/mehr-een/bemkl-rbps. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
format Online
Article
Text
id pubmed-5905617
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-59056172018-04-23 Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach Ali, Mehreen Khan, Suleiman A Wennerberg, Krister Aittokallio, Tero Bioinformatics Original Papers MOTIVATION: Proteomics profiling is increasingly being used for molecular stratification of cancer patients and cell-line panels. However, systematic assessment of the predictive power of large-scale proteomic technologies across various drug classes and cancer types is currently lacking. To that end, we carried out the first pan-cancer, multi-omics comparative analysis of the relative performance of two proteomic technologies, targeted reverse phase protein array (RPPA) and global mass spectrometry (MS), in terms of their accuracy for predicting the sensitivity of cancer cells to both cytotoxic chemotherapeutics and molecularly targeted anticancer compounds. RESULTS: Our results in two cell-line panels demonstrate how MS profiling improves drug response predictions beyond that of the RPPA or the other omics profiles when used alone. However, frequent missing MS data values complicate its use in predictive modeling and required additional filtering, such as focusing on completely measured or known oncoproteins, to obtain maximal predictive performance. Rather strikingly, the two proteomics profiles provided complementary predictive signal both for the cytotoxic and targeted compounds. Further, information about the cellular-abundance of primary target proteins was found critical for predicting the response of targeted compounds, although the non-target features also contributed significantly to the predictive power. The clinical relevance of the selected protein markers was confirmed in cancer patient data. These results provide novel insights into the relative performance and optimal use of the widely applied proteomic technologies, MS and RPPA, which should prove useful in translational applications, such as defining the best combination of omics technologies and marker panels for understanding and predicting drug sensitivities in cancer patients. AVAILABILITY AND IMPLEMENTATION: Processed datasets, R as well as Matlab implementations of the methods are available at https://github.com/mehr-een/bemkl-rbps. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Oxford University Press 2018-04-15 2017-11-27 /pmc/articles/PMC5905617/ /pubmed/29186355 http://dx.doi.org/10.1093/bioinformatics/btx766 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Papers
Ali, Mehreen
Khan, Suleiman A
Wennerberg, Krister
Aittokallio, Tero
Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title_full Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title_fullStr Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title_full_unstemmed Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title_short Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
title_sort global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905617/
https://www.ncbi.nlm.nih.gov/pubmed/29186355
http://dx.doi.org/10.1093/bioinformatics/btx766
work_keys_str_mv AT alimehreen globalproteomicsprofilingimprovesdrugsensitivitypredictionresultsfromamultiomicspancancermodelingapproach
AT khansuleimana globalproteomicsprofilingimprovesdrugsensitivitypredictionresultsfromamultiomicspancancermodelingapproach
AT wennerbergkrister globalproteomicsprofilingimprovesdrugsensitivitypredictionresultsfromamultiomicspancancermodelingapproach
AT aittokalliotero globalproteomicsprofilingimprovesdrugsensitivitypredictionresultsfromamultiomicspancancermodelingapproach